198 related articles for article (PubMed ID: 37821996)
1. FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma.
Tang X; Luo B; Huang S; Jiang J; Chen Y; Ren W; Shi X; Zhang W; Shi L; Zhong X; Lü M
Eur J Med Res; 2023 Oct; 28(1):419. PubMed ID: 37821996
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of
Komatsu H; Masuda T; Iguchi T; Nambara S; Sato K; Hu Q; Hirata H; Ito S; Eguchi H; Sugimachi K; Eguchi H; Doki Y; Mori M; Mimori K
Anticancer Res; 2017 Mar; 37(3):1083-1090. PubMed ID: 28314268
[TBL] [Abstract][Full Text] [Related]
3. LncRNA SNHG1 upregulates FANCD2 and G6PD to suppress ferroptosis by sponging miR-199a-5p/3p in hepatocellular carcinoma.
Zhou L; Zhang Q; Cheng J; Shen X; Li J; Chen M; Zhou C; Zhou J
Drug Discov Ther; 2023 Sep; 17(4):248-256. PubMed ID: 37599085
[TBL] [Abstract][Full Text] [Related]
4. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
5. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
6. Integrative analyses of prognosis, tumor immunity, and ceRNA network of the ferroptosis-associated gene FANCD2 in hepatocellular carcinoma.
Yang Z; Song Y; Li Y; Mao Y; Du G; Tan B; Zhang H
Front Genet; 2022; 13():955225. PubMed ID: 36246623
[TBL] [Abstract][Full Text] [Related]
7. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
8. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Xu H; Xiong C; Chen Y; Zhang C; Bai D
Bioengineered; 2021 Dec; 12(1):2664-2675. PubMed ID: 34115569
[TBL] [Abstract][Full Text] [Related]
9. [Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].
Wang H; Li W; Zhang D
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Apr; 42(4):473-485. PubMed ID: 35527483
[TBL] [Abstract][Full Text] [Related]
10. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis of the tumorigenic role of Fanconi anemia complementation group D2 (FANCD2) in human tumors.
Xie X; Zhao Y; Du F; Cai B; Fang Z; Liu Y; Sang Y; Ma C; Liu Z; Yu X; Zhang C; Jiang J; Gao Z; Liu Y; Lin X; Jing H; Zhong X; Cong L; Dai H; Sha D; Shao N; Feng H; Li L; Liu J; Shang L
Genomics; 2024 Jan; 116(1):110762. PubMed ID: 38104669
[TBL] [Abstract][Full Text] [Related]
12. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma.
Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X
Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186
[No Abstract] [Full Text] [Related]
13. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
14. Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
Zhong Z; Xu M; Tan J
Pathol Oncol Res; 2022; 28():1610670. PubMed ID: 36277962
[No Abstract] [Full Text] [Related]
15. Upregulation of Ferroptosis-Related Fanconi Anemia Group D2 is a Poor Prognostic Factor and an Indicator of Tumor Immune Cell Infiltration in Lung Adenocarcinoma.
Zhang J; Wang D; Chen X; Ji L; Yu M; Guo M; Zhang D; Chen W; Xu F
Front Genet; 2022; 13():825685. PubMed ID: 35646059
[TBL] [Abstract][Full Text] [Related]
16. Pancancer analysis of the prognostic and immunological role of FANCD2: a potential target for carcinogenesis and survival.
Zhao Z; Wang R; Wang R; Song J; Ma F; Pan H; Gao C; Wang D; Chen X; Fan X
BMC Med Genomics; 2024 Mar; 17(1):69. PubMed ID: 38443946
[TBL] [Abstract][Full Text] [Related]
17. Fanconi Anemia Complementation Group E, a DNA Repair-Related Gene, Is a Potential Marker of Poor Prognosis in Hepatocellular Carcinoma.
Takahashi J; Masuda T; Kitagawa A; Tobo T; Nakano Y; Abe T; Ando Y; Kosai K; Kobayashi Y; Matsumoto Y; Yoshizumi T; Mori M; Mimori K
Oncology; 2022; 100(2):101-113. PubMed ID: 34724663
[TBL] [Abstract][Full Text] [Related]
18. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
20. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
